The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Abstract
DCs are critical cellular targets of PD-L1 blockade in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is not surprising given that PD-L1 blockade inhibits not only the PD-1/PD-L1 axis but also PD-L1/CD80 cis interactions on DCs, freeing more CD80 molecules to enhance T cell priming (63).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [63]
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336 · cited 1×
“1 is sequestered by the more abundantly expressed PD-L1 and therefore less capable of costimulating CD28 on the T cells (24).”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“For this purpose, we sought for a DC gene signature in pretreatment tumor specimens from patients with RCC enrolled into a phase 1 study (NCT01375842) of atezolizumab (anti–PD-L1) (n = 56) (4) and patients with non–small cell lung cancer (NSCLC) enrolled into the randomized phase 2 study POPLAR (NCT01903993) of atezol…”
BackgroundMethodSelf-citationRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Self-citationPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Self-citation
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Metadata
- Authors
- Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., Rommel, K., Matos, I., Colombetti, S., Belousov, A., Karanikas, V., Ossendorp, F., Hegde, P. S., Chen, D. S., Umana, P., Perro, M., Klein, C., & Xu, W.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Cancer Immunotherapy Discovery, Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren 8952, Switzerland.
- Leiden University Medical Center (NL)
- Genentech (US)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Xu, Wei
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-03-11
- Volume
- 12
- Issue
- 534
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3011497962
- Cited by
- 394
- References
- 29
- Citations by year
- 2026: 46 · 2025: 49 · 2024: 67 · 2023: 70 · 2022: 58 · 2021: 68 · 2020: 36
- FWCI
- 20.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dendritic cells, PD-L1 blockade, PD-1, B7-1 (CD80), CD28, T cell priming, cancer immunotherapy, atezolizumab, renal cell carcinoma, non-small cell lung cancer, tumor-associated dendritic cells, overall survival, immune checkpoint
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Dendritic Cells, Humans, Immunotherapy, Lung Neoplasms, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. https://app.cochat.ai/papers/10.1126/scitranslmed.aav7431
- The paper
- Mayoux, M., Roller, A., Pulko, V., Sammicheli, S., Chen, S., Sum, E., Jost, C., Fransen, M. F., Buser, R. B., Kowanetz, M., Rommel, K., Matos, I., Colombetti, S., Belousov, A., Karanikas, V., Ossendorp, F., Hegde, P. S., Chen, D. S., Umana, P., . . . Xu, W. (2020). Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aav7431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.